Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals

BACKGROUND & AIMS: The approval of all-oral direct-acting antiviral (DAA) regimens for the treatment of hepatitis C virus (HCV) has led to the expansion of therapy to include patients with cirrhosis who have hepatocellular carcinoma (HCC). Data on the use of DAAs in HCV+ patients with HCC is lim...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Hepatol
Auteurs principaux: Prenner, Stacey B., VanWagner, Lisa B., Flamm, Steven L., Salem, Riad, Lewandowski, Robert J., Kulik, Laura
Format: Artigo
Langue:Inglês
Publié: 2017
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5776681/
https://ncbi.nlm.nih.gov/pubmed/28161470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhep.2017.01.020
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires